These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 9742636)
1. [The efficacy of polychemotherapy programs in treating multiple myeloma patients]. Bessmel'tsev SS; Abdulkadyrov KM; Rukavitsyn OA Ter Arkh; 1998; 70(7):46-9. PubMed ID: 9742636 [TBL] [Abstract][Full Text] [Related]
2. [Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma]. Wutke K; Anger G Z Gesamte Inn Med; 1983 Dec; 38(23):630-3. PubMed ID: 6689459 [TBL] [Abstract][Full Text] [Related]
4. [Clinical trial of alpha-interferon (human lymphoblastoid interferon) in combination with VCAP chemotherapy in multiple myeloma]. Umeda M; Shirai T; Tsukahara T; Kaneko H; Yamauchi M; Arai N; Kosuge T; Kato M; Shikoshi K; Anno S Rinsho Ketsueki; 1991 Jun; 32(6):669-74. PubMed ID: 1890744 [TBL] [Abstract][Full Text] [Related]
5. Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma. Galli M; Nicolucci A; Valentini M; Belfiglio M; Delaini F; Crippa C; Barbui AM; Giussani U; Rambaldi A; Barbui T Haematologica; 2005 Dec; 90(12):1643-9. PubMed ID: 16330437 [TBL] [Abstract][Full Text] [Related]
6. [Relationship between prognosis of multiple myeloma and response to VCAP therapy]. Umeda M; Annoh S; Takata M; Shikoshi K; Katoh M; Shirai T Rinsho Ketsueki; 1994 Mar; 35(3):272-8. PubMed ID: 8158848 [TBL] [Abstract][Full Text] [Related]
7. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521 [TBL] [Abstract][Full Text] [Related]
8. [Heterogenicity of the response to chemotherapy in plasmablastic myeloma]. Paule B; Quillard J; Bisson M; Massias P Nouv Rev Fr Hematol (1978); 1987; 29(6):391-6. PubMed ID: 2454453 [TBL] [Abstract][Full Text] [Related]
9. [Chemotherapy of multiple myeloma]. Golenkov AK Sov Med; 1991; (3):43-6. PubMed ID: 1882290 [No Abstract] [Full Text] [Related]
10. [Results with the use of the M-2 protocol in plasmacytoma]. Ho AD; Wittkamp S; Theml H; Keilholz U; Hunstein W Dtsch Med Wochenschr; 1986 May; 111(22):858-61. PubMed ID: 3754811 [TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol). Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205 [TBL] [Abstract][Full Text] [Related]
12. [Combination chemotherapy of multiple myeloma]. Uzuka Y; Saito Y; Ito T Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1481-7. PubMed ID: 2389944 [TBL] [Abstract][Full Text] [Related]
14. Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial. Scheithauer W; Cortelezzi A; Fritz E; Kührer I; Polli E; Baldini L; Ludwig H J Biol Response Mod; 1989 Apr; 8(2):109-15. PubMed ID: 2659740 [TBL] [Abstract][Full Text] [Related]
15. [Combined treatment, polychemotherapy and amino-hydroxybutylidene-diphosphonate, of a patient with multiple myeloma: remission and long survival]. Attardo-Parrinello G; Merlini G; Crema F; Fiorentini ML; Mazzone A; Cotti-Piccinelli E Medicina (Firenze); 1988; 8(3):318-20. PubMed ID: 3231044 [No Abstract] [Full Text] [Related]
16. [VCAP therapy of multiple myeloma]. Umeda M; Kaneko H; Katoh M; Yamaguchi R; Masaki T; Ishikawa I; Yamauchi M; Kiga Y; Hara A; Nojima Z Rinsho Ketsueki; 1987 Jul; 28(7):1147-51. PubMed ID: 3694822 [No Abstract] [Full Text] [Related]
17. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. Tsukasaki K; Utsunomiya A; Fukuda H; Shibata T; Fukushima T; Takatsuka Y; Ikeda S; Masuda M; Nagoshi H; Ueda R; Tamura K; Sano M; Momita S; Yamaguchi K; Kawano F; Hanada S; Tobinai K; Shimoyama M; Hotta T; Tomonaga M; J Clin Oncol; 2007 Dec; 25(34):5458-64. PubMed ID: 17968021 [TBL] [Abstract][Full Text] [Related]
18. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. van 't Veer MB; de Jong D; MacKenzie M; Kluin-Nelemans HC; van Oers MH; Zijlstra J; Hagenbeek A; van Putten WL Br J Haematol; 2009 Feb; 144(4):524-30. PubMed ID: 19036081 [TBL] [Abstract][Full Text] [Related]
19. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S; Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805 [TBL] [Abstract][Full Text] [Related]
20. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study. Tribalto M; Amadori S; Cudillo L; Caravita T; Del Poeta G; Meloni G; Avvisati G; Petrucci MT; Pulsoni A; Leone G; Sica S; Martelli M; Tabilio A; Fioritoni G; Majolino I; Mandelli F Haematologica; 2000 Jan; 85(1):52-8. PubMed ID: 10629592 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]